Open this publication in new window or tab >>Department of Translational Medical Oncology, National Center for Tumor Diseases (NCT) Heidelberg, German Cancer Research Center (DKFZ), Heidelberg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Department of Microbiology, Tumor and Cell Biology, Clinical Genomics Facility, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden; Genomic Medicine Sweden (GMS), Sweden.
Department of Internal Medicine I, University of Ulm, Ulm, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Genomic Medicine Sweden (GMS), Sweden.
Department of Hematology, Oncology and Stem Cell Transplantation, Faculty of Medicine, University Medical Center Freiburg, University of Freiburg, Freiburg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Department of Microbiology, Tumor and Cell Biology, Clinical Genomics Facility, Science for Life Laboratory, Karolinska Institutet, Solna, Sweden; Genomic Medicine Sweden (GMS), Sweden.
Department of Medicine II, University Medical Center, Freiburg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Department of Laboratory Medicine, Division of Clinical Genetics, Lund University, Lund, Sweden; Genomic Medicine Sweden (GMS), Sweden.
Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Medical Genetics and Genomics, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden; Genomic Medicine Sweden (GMS), Sweden.
Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Department of Internal Medicine I, University Hospital Tübingen, Tübingen, Germany; Centers for Personalized Medicine (ZPM) Baden-Wuerttemberg, Germany.
Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden; Genomic Medicine Sweden (GMS), Sweden.
Linköping University, Department of Health, Medicine and Caring Sciences, Division of Society and Health. Linköping University, Faculty of Medicine and Health Sciences.
Linköping University, Department of Biomedical and Clinical Sciences, Division of Neurobiology. Linköping University, Faculty of Medicine and Health Sciences. Region Östergötland, Center for Diagnostics, Clinical pathology.
Show others...
2022 (English)In: Seminars in Cancer Biology, ISSN 1044-579X, E-ISSN 1096-3650, Vol. 84, p. 242-254Article in journal (Refereed) Published
Abstract [en]
Over the last decades, rapid technological and scientific advances have led to a merge of molecular sciences and clinical medicine, resulting in a better understanding of disease mechanisms and the development of novel therapies that exploit specific molecular lesions or profiles driving disease. Precision oncology is here used as an example, illustrating the potential of precision/personalized medicine that also holds great promise in other medical fields. Real-world implementation can only be achieved by dedicated healthcare connected centers which amass and build up interdisciplinary expertise reflecting the complexity of precision medicine. Networks of such centers are ideally suited for a nation-wide outreach offering access to precision medicine to patients independent of their place of residence. Two of these multicentric initiatives, Genomic Medicine Sweden (GMS) and the Centers for Personalized Medicine (ZPM) initiative in Germany have teamed up to present and share their views on core concepts, potentials, challenges, and future developments in precision medicine. Together with other initiatives worldwide, GMS and ZPM aim at providing a robust and sustainable framework, covering all components from technology development to clinical trials, ethical and legal aspects as well as involvement of all relevant stakeholders, including patients and policymakers in the field.
Place, publisher, year, edition, pages
Elsevier, 2022
Keywords
Cancer; Clinical trials; Molecular profiling; Personalized medicine; Precision medicine
National Category
Clinical Laboratory Medicine
Identifiers
urn:nbn:se:liu:diva-192710 (URN)10.1016/j.semcancer.2021.05.026 (DOI)000830066100004 ()34033893 (PubMedID)2-s2.0-85111382323 (Scopus ID)
Funder
Vinnova
2023-03-282023-03-282023-04-04Bibliographically approved